Pharmaceutical plastic bottle manufacturers are increasingly focusing on material and design innovations, including smart dosing functions to better ensure patient compliance.

Dubai, United Arab Emirates – August 9, 2021 / MarketersMedia / –

the pharmaceutical plastic bottles market the value will rise to US $ 29.6 billion in 2021, according to Future Market Insights (IMF). Driven by the expansion of the healthcare industry, the market is expected to grow at a CAGR of 10.3% during the assessment period 2021-2031. Despite the logistical challenges amid the restrictions imposed to contain the pandemic in 2020, the market is expected to register 10.0% year-over-year growth in 2021.

The paradigm shift in consumer behavior towards adoption of sustainable packaging solutions is fueling market growth. Features such as low weight and cost effectiveness boost sales. Advances in the healthcare industry have driven demand for efficient and cost-effective packaging solutions, creating lucrative growth opportunities.

The increasing possibilities of corticosteroid drug applications in nasal formulations for a large number of treatments are boosting sales prospects. IMF has estimated that plastic bottles for ophthalmic / nasal formulations will account for more than 42.7% of pharmaceutical plastic bottle sales in 2021.

For a sample copy of the visit report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7750

Demand continues to grow for polyethylene terephthalate (PET) offerings due to its high barrier resistance and recyclability, thus driving market growth. According to the study, PET is expected to grow at a CAGR of 11.3% during the forecast period 2021-2031, surpassing a valuation of US $ 8.3 billion in 2021.

North America will remain a very lucrative market. The increase in health care spending will allow the United States to dominate the market in North America. It is set to grow 2.5 times the size of its current market through 2031, accounting for over 79.3% of the North American market by the end of 2031.

“The emergence of technological advancements, including child resistant closures and counterfeit protection solutions, is boosting the adoption of pharmaceutical plastic bottles, especially in developed countries,” said an analyst from Future Market Insights.

Key Points From Pharmaceutical Plastic Bottles Market Research

Supported by the presence of advanced healthcare infrastructure, the UK market is expected to grow at a CAGR of 8% during the forecast period.
The Chinese market is expected to grow at a CAGR of 11.4%, accounting for over 59% of the pharmaceutical plastic bottle market in East Asia.
The Indian market is expected to grow at a significant rate, surpassing a valuation of US $ 1.9 billion in 2021, supported by a large patient population.
The United States dominates the pharmaceutical plastic bottle market in North America and is expected to account for nearly 79.3% of sales through 2031.
Polyethylene terephthalate (PET) is expected to exceed a valuation of US $ 8.3 billion in 2021, thanks to recycling and durability characteristics.

Key factors

The growing demand for sustainable packaging solutions is driving the growth of the market.
The emergence of technological innovations contributes to the growth of the market.

Key restrictions

The COVID-19 virus outbreak is a major factor hindering growth.
Growing environmental concerns regarding the use of plastic will pose a challenge to adoption.

Request the table of contents @ https://www.futuremarketinsights.com/toc/rep-gb-7750

Competitive landscape

Pharmaceutical plastic bottle manufacturers are focused on making expansions and acquisitions to strengthen their global presence.

In July 2019, Berry Global Inc. announced the acquisition of RPC Group. This acquisition will help strengthen the combined platform of the two organizations with product design and expertise.
In January 2021, ALPLA Werke Alwin Lehner GmbH & Co KG, one of the world’s leading producers of plastic packaging, announced an investment of over five million dollars in an extrusion system for the production of recycled PET in Italy.

Some of the major players operating in the Pharmaceutical Plastic Bottle Market presented by Future Market Insights are:

Berry Global Inc.
Amcor Plc
Gerresheimer AG
AptarGroup, Inc.
Berk Company, LLC
Alpha Packaging Holdings, Inc.
Comar, LLC
Alpack Inc.
ALPLA Werke Alwin Lehner GmbH & Co KG
Pharmaceutical Plastics Group
Spa Bormioli Pharma
L. Smith Company
United States Plastics Company
Weener Plastics Group BV
Pharmaceutical packaging
Pretium packaging company
Packaging Group Pro-Pac Pty Ltd

More valuable market information

IMF in its new report offers an unbiased analysis of the global pharmaceutical plastic bottles market, analyzing forecast statistics through to 2021 and beyond. The survey reveals growth projections in the pharmaceutical plastic bottles market with detailed segmentation:

By type of bottle

Plastic bottles for solid formulation
Plastic bottles for liquid
Plastic bottles for ophthalmic / nasal formulation

By type of material

Polyethylene (PE)

High density polyethylene (HDPE)
Low density polyethylene (LDPE)

Polyethylene terephthalate (PET)
Polypropylene (PP)
Polyvinyl Chloride (PVC)

By capacity

Below 100 ml
100 ml – 250 ml
Above 250 ml

By region

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)

Key Questions Answered In The Pharmaceutical Plastic Bottles Market Report

The report offers detailed information on the demand outlook for Pharmaceutical Plastic Bottles for 2021-2031
The market study also highlights the expected sales growth for the pharmaceutical plastic bottles market between 2021 and 2031.
The Pharmaceutical Plastic Bottles market research identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluating the current market size and forecast and technological advancement in the market. within the industry
Analysis of pharmaceutical plastic bottles market share of key companies in the industry and coverage of strategies such as mergers and acquisitions, joint ventures, collaborations or partnerships, etc.

Contact information:
Name: Mr. Abhishek Budholiya
E-mail: Send an email
Organization: Future Market Outlook
Website: https://www.futuremarketinsights.com/reports/pharmaceutical-plastic-bottles-market

Source URL: https://marketersmedia.com/radio-fréquence-identification-rfid-integration-in-pharmaceutical-plastic-bottles-to-drive-growth-at-103-cagr-through-2031-future-market-insights/89040796

Source: Marketers Media

Version number: 89040796

COMTEX_391247487 / 2773 / 2021-08-09T07: 26: 33

The ‘Pharmaceutical Solvents Market’ study from ‘The Insight Partners’ provides details of market dynamics affecting the market, market scope, market segmentation, and shadow overlays on key market players, highlighting the favorable competitive landscape and prevailing trends over the years.
This report contains a comprehensive analysis of the market and is assessed using validated volume and value data from three approaches, including the revenue of leading companies. It ends with accurate and authentic market estimates taking into account all parameters and market dynamics. Every crucial and decisive detail for the development and restriction of the market is mentioned in detail along with solutions and suggestions which may affect the market in the near future. Market segmentation is studied specifically to give in-depth knowledge of additional investments in the market.

For a sample report, click: https://bit.ly/3lChcgD

The report “Pharmaceutical Solvents Market” gives a varied description of the market segmentation on the basis of segmented dosage, route of administration and application, and offers a descriptive structure of trends and restrictions of different segments and sub-segments. It also provides the market size and estimates a forecast for the year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South and Central America. The report also provides exhaustive PEST analysis for all five regions after evaluating the political, economic, social, and technological factors affecting the Typhoid Vaccines market.

The report facilitates the determination and interpretation of the major market players, portfolios containing the necessary information such as company profiles, components and services offered, financial information of recent years, key developments of recent years, that help strategize to gain competitive advantage in the long run. The report also analyzes factors affecting the pharmaceutical solvents market from the demand and supply side and further assesses the market dynamics affecting the market during the forecast period i.e. the drivers. , constraints, opportunities and future trends.

Companies mentioned:
1. Mitsubishi Chemical Corporation
2. BASF SE
3. Merck KGaA
4. Exxon Mobil Corporation
5. Bayer SA
6. Eastman Chemical Company
7. Du Pont de Nemours, Inc
8. Nouryon
9. Pon Pure Chemicals
10. FINAR LIMITED

Key elements recognized by the report:
• Market size and growth rate over the forecast period.
• Key factors driving the “Pharmaceutical Solvents Market” market.
• Key market trends accelerating the growth of the “Pharmaceutical Solvents Market” market.
• Challenges to market growth.
• The main suppliers of the “Pharmaceutical solvents market” market.
• Detailed SWOT analysis.
• Opportunities and threats faced by existing vendors in the Global “XYZ” Market.
• Trending factors influencing the market in geographic regions.
• Strategic initiatives targeting major suppliers.
• PEST analysis of the market in the five major regions.

Buy the full report at: https://bit.ly/3isSz3T

Contact us:
Call: + 1-646-491-9876
Email: [email protected]

About Us:
The Insight Partners is a one-stop-shop for industrial research in actionable intelligence. We help our clients find solutions to their research needs through our syndicated research and advisory services. We are a technology, healthcare, manufacturing, automotive and defense specialist.

This version was posted on openPR.

TAIPEI, August 5, 2021 / PRNewswire / – KYOWA Pharmaceutical Industry Co. Ltd., a leading Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacture of generic products for deposit in Japan. KYOWA will be the first Japanese customer for the Bora manufacturing site in Zhunan, already approved by the USFDA, MHRA and TFDA.

This project will coordinate manufacturing forces in Taiwan and increase the visibility of from Taiwan pharmaceutical capabilities. It further demonstrates the cooperation between from Japan and from Taiwan pharmaceutical companies.

The batches produced will be used to further support bioequivalence (BE) studies and then submitted to from Japan PMDA for approval. After PMDA approval, Bora will be the commercial manufacturing site for the production of generic products. Bora Pharmaceuticals’ sites already have an excellent track record with many regulatory bodies around the world, including USFDA, MHRA, TFDA, ANVISA, Health Canada and many more.

About Bora Pharmaceuticals:

Bora Pharmaceuticals is a leading international CGMP CDMO specializing in complex oral solid assays, non-sterile liquids, nasal sprays, and semi-solid Rx and OTC pharmaceuticals for clinical to commercial phase manufacturing and packaging. Bora owns and operates three state-of-the-art CGMP manufacturing facilities (Taiwan and Canada) built to the highest international standards for manufacturing, packaging, R&D and analytical testing. Our TAA compliant sites deliver to over 100 markets around the world, including the United States, Canada, EU, South East Asia, Middle East, and South and Central America. Bora handles high potency compounds, solvents, flammables and products with IR / SR / ER release profile. For more information visit: www.boracorpcdmo.com

About KYOWA Pharmaceutical Industry Co. Ltd. :

KYOWA Pharmaceutical Industry Co. Ltd. was established in 1954 and is a leading generic pharmaceutical company. Its best-known generic drug in Japan is known as “AMEL”. The company mainly focuses on the central nervous system (CNS) market. KYOWA will help patients and their families as a total CNS solutions company that provides comprehensive lifelong support from disease prevention and therapy to promoting a long healthy life. and prognosis. KYOWA’s portfolio consists of over 300 products and around 60% of drugs are CNS related. For more information visit: https://www.kyowayakuhin.co.jp/

SOURCE Bora Pharma

The Global Oral Solid Dose Pharmaceutical Formulation Market is fueled by various factors, according to a detailed assessment explained in the report. This study shows how important an in-depth analysis must be and how greatly it affects the quality of information provided to readers. In addition, the report also takes into account the impact of the novel COVID-19 pandemic on the market Solid oral pharmaceutical formulation and offers a clear assessment of the projected market fluctuations over the forecast period.

Oral Solid Dose Pharmaceutical Formulation Market The report provides an in-depth examination of the expansion drivers, potential challenges, distinguishing trends and opportunities for the market players enabling the readers to fully understand the market landscape of the Solid Oral Pharmaceutical Formulation. The top major key manufacturers included in the report alongside market share, inventory determinations and figures, contact details, sales, capacity, production, price, cost, revenue and profiles commercial. The primary objective of the Oral Solid Dose Pharmaceutical Formulation industry report is to provide key insights into competitive positioning, current trends, market potential, growth rates, and alternative relevant statistics.

Sample request with complete table of contents and figures and graphics @ https://crediblemarkets.com/sample-request/oral-solid-dosage-pharmaceutical-formulation-market-507467?utm_source=Akhilesh&utm_medium=SatPR

By the main key players

Novartis AG
Pfizer Inc
Gilead Sciences, Inc.
AbbVie Inc.
Merck & Co. Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Eli Lilly and company

By types

Tablets
Capsules
Lozenges

By applications

Hospital pharmacies
Retail pharmacies
Online pharmacies
Pharmacies

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical and forecast (2015-2027): United States, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Colombia, Chile, Saudi Arabia, United Arab Emirates, Egypt, Nigeria, South Africa and rest of the world

Direct purchase this market research report now @ https://crediblemarkets.com/reports/purchase/oral-solid-dosage-pharmaceutical-formulation-market-507467?license_type=single_user;utm_source=Akhilesh&utm_medium=SatPR

Some points from the table of contents

Global Oral Solid Dose Pharmaceutical Formulations Market Research Report with Opportunities and Strategies to Drive Growth – Impact and Recovery of COVID-19

1 Market overview

2 Market dynamics

3 Assessment of the associated industry

4 Competitive market landscape

5 Analysis of leading companies

6 Market Analysis and Forecast, by Product Types

7 Market Analysis and Forecast, by Applications

8 Market Analysis and Forecast, by Regions

9 North America Oral Solid Dose Pharmaceutical Formulations Market Analysis

10 Europe Oral Solid Dose Pharmaceutical Formulations Market Analysis

11 Asia-Pacific Oral Solid Dose Pharmaceutical Formulations Market Analysis

12 South America Oral Solid Dose Pharmaceutical Formulations Market Analysis

13 Middle East & Africa Oral Solid Dose Pharmaceutical Formulations Market Analysis

14 Conclusions and recommendations

15 Annex

Do you have a specific question or requirement? Ask our industry expert @ https://crediblemarkets.com/enquire-request/oral-solid-dosage-pharmaceutical-formulation-market-507467?utm_source=Akhilesh&utm_medium=SatPR

Main information that the study will provide:

• 360 Degree Oral Solid Dose Pharmaceutical Formulations Market Overview Based On Global And Regional Level
• Market share and sales revenue by key players and emerging regional players
• Competitors – In this section, various leading players of the Solid Oral Pharmaceutical Formulation industry are studied on the basis of their company profile, product portfolio, capacity, price, cost and revenue.
• A separate chapter on the entropy of the oral solid dose pharmaceutical formulations market to better understand the aggressiveness of the market leaders [Merger & Acquisition / Recent Investment and Key Developments]
• Patent analysis Number of patents / Trademark registered in recent years.

Contact us:

Credible markets
99 Wall Street 2124 New York, NY 10005
E-mail- [email protected]

Read the article

From the point of view of the pharmaceutical industry, water activity is an important indicator because it indicates the amount of water available for a drug to react with other substances.

Numerous studies have been conducted at Cilicant to understand the processes underlying the challenges that prescribers and manufacturers face in drug packaging. Only then can we develop products that tackle the problems that cause drugs to deteriorate.

One of the areas in which we have invested a lot is, as is more commonly known, research related to water activity, or equilibrium relative humidity (HRE). The results show that the use of relative humidity regulators is the best choice of desiccant when the water activity needs to be kept within a narrow range.

To understand why, we need to examine the science behind it.

Definition and determination of water activity

Water activity is defined as the ratio of the vapor pressure of water in a particular sample (NOT.) Up to the vapor pressure of pure water (NOT.₀) At the same temperature. The formula used is:

Pure water has a water activity of 1.0, but other substances decrease from this upper limit to a water activity value of 0.0 along the sliding scale, indicating that ‘they are completely dry. For packaged drugs, it is more convenient to express water activity from the point of view of the ERH of the sealed system. ERH represents the activity of water as a function of the packaging environment, and the relationship between the two is expressed by the following equation.

Second, “water activity” and “moisture content” are different concepts, so it is important to understand these differences. The water (or water) content of a drug is typically used to represent the percentage of water molecules in a product, but water activity is a measure of the reactivity of those water molecules.

There is no straightforward official approach to plotting the relationship between water content and water activity, but changes in the relationship between water content and water activity are known. referred to as “moisture absorption isotherms” and can be determined drug by drug. .. As the composition of the product changes, the adsorption isotherm also changes.

There are several ways to measure the water activity of a medicine. The dew point method or the cooled mirror method is the gold standard. Here, a dedicated device measures the temperature at which air (in moisture equilibrium) condenses on a polished cooling mirror exposed to a test sample of the product. This temperature is called the dew point and determines the estimated relative humidity of the sample. Other approaches include the use of capacitive humidity sensors or resistive humidity sensors.

Water activity and drug protection

From the point of view of the pharmaceutical industry, water activity is an important indicator because it indicates the amount of water available for a drug to react with other substances. Unlike water content, water activity explains the energy level of that water and affects the shelf life of the drug.

Since drugs have different water activity values, measuring water activity can be used to assess a drug’s resistance to microbial contaminants. You can then evaluate the best way to package the product to maintain the optimum water activity range for microbial growth.

Of course, the drugs are offered in a combination of forms such as capsules and powders, depending on the most efficient delivery mechanism to induce the effect of the drug on the human body. What is important is the difference in water activity between the two materials. As water moves from areas of high aquatic activity to areas of low aquatic activity, the deviation can lead to problems such as cracking of capsules and increased water activity of powders.

Many pharmaceutical packaging solutions incorporate the use of one or more desiccants to regulate humidity levels. Together they are intended to reduce water activity and protect the product from other spoilage problems due to microbial growth and water accumulation. However, these “standard” desiccants can cause overdrying if the ERH of the packaging environment is to be kept within certain limits.

Introducing ACCUFLIP: A Better Way to Regulate Water Activity

Cilicant solved this problem by creating a new product line, ACCUFLIP. These moisture regulating adsorbents, or moisture regulating agents, are a new type of desiccator designed to maintain stable ERH in the package. Unlike traditional standard desiccants, which can be too aggressive when reducing humidity, humidity adjusted adsorbents maintain optimal levels of ERH in the package, allowing for optimal shelf life. Additionally, these moisture regulating adsorbents can be adjusted to meet specified ERH level requirements, making them extremely versatile and ideal for a wide range of pharmaceutical packaging scenarios.

application

Humidity controllers can regulate the water activity of all forms of pharmaceuticals, so their potential for application is enormous.

For example, in capsules, the water activity of the outer coating should be maintained at a level that prevents the coating from becoming brittle due to very low ERH and sticky due to high ERH. The moisture regulating adsorbent absorbs and releases moisture as needed to maintain constant ERH, thus protecting the gel capsule from high and low ERH. Standard desiccators are ineffective in this case because they actively remove water from the environment, have very low ERH and water activity, and can make the capsule brittle.

Another use can be seen in dry powder inhalers, which are widely used to deliver drug doses to the lungs. It is imperative that these devices are packaged in a stable ERH environment, as fluctuations in humidity adversely affect product stability and end user efficiency. If the ERH is high here, the powder particles will aggregate and the effective delivery of the drug to the lungs will be a problem. Here, the humidity adjusting adsorbent prevents the humidity level from being too high or too low. Standard desiccants can become too dry, producing static charges and reducing the dose available to lung tissue.

ACCUFLIP – A new tool for pharmaceutical packaging

It is clear that the importance of well-regulated water activity in the stability of many pharmaceutical dosage forms cannot be overstated. Traditional standard desiccants can reduce water activity in the packaging environment and extend the shelf life of the drug, but they can also cause overdrying. In these scenarios, moisture regulating adsorbents such as ACCUFLIP provide an effective alternative to help maintain optimal levels of ERH in packaged drugs and extend shelf life.

Cilicant is constantly on the lookout for new and innovative ways to solve the problems of its customers in the pharmaceutical industry, and as products requiring strict ERH levels come to market, these desiccants are introduced into the pharmaceutical industry. pharmaceutical packaging. I think he will play an important role.

To view the full white paper linked to this article, please visit www.cilicant.com.

(The information provided by Cilicant Chem Private Limited is for general information purposes only and no one can trust it for any other purpose. The Company expressly or implied with respect to the accuracy, validity and effectiveness . No representations or warranties of any kind are made. Cilicant Chem Private Limited owns all intellectual property rights relating to the content of this article. The content of this article is prior in writing to Cilicant Chem Private. No reproduction or reproduction may not be made in any way without the permission of. Limited. CilicantChemPrivate Limited is direct, indirect, incidental, consequential or disciplinary due to the reliance on the data described in this article. We will not be responsible for any damage or loss.)